{"pmid":32414646,"title":"ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.","text":["ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged in Chinese people in December 2019 and has currently spread worldwide causing the COVID-19 pandemic with more than 150,000 deaths. In order for a SARS-CoV like virus circulating in wild life for a very long time to infect the index case-patient, a number of conditions must be met, foremost among which is the encounter with humans and the presence in homo sapiens of a cellular receptor allowing the virus to bind. Recently it was shown that the SARS-CoV-2 spike protein, binds to the human angiotensin I converting enzyme 2 (ACE2). This molecule is a peptidase expressed at the surface of lung epithelial cells and other tissues, that regulates the renin-angiotensin-aldosterone system. Humans are not equal with respect to the expression levels of the cellular ACE2. Moreover, ACE2 polymorphisms were recently described in human populations. Here we review the most recent evidence that ACE2 expression and/or polymorphism could influence both the susceptibility of people to SARS-CoV-2 infection and the outcome of the COVID-19 disease. Further exploration of the relationship between the virus, the peptidase function of ACE2 and the levels of angiotensin II in SARS-CoV-2 infected patients should help to better understand the pathophysiology of the disease and the multi-organ failures observed in severe COVID-19 cases, particularly heart failure.","J Microbiol Immunol Infect","Devaux, Christian A","Rolain, Jean-Marc","Raoult, Didier","32414646"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged in Chinese people in December 2019 and has currently spread worldwide causing the COVID-19 pandemic with more than 150,000 deaths. In order for a SARS-CoV like virus circulating in wild life for a very long time to infect the index case-patient, a number of conditions must be met, foremost among which is the encounter with humans and the presence in homo sapiens of a cellular receptor allowing the virus to bind. Recently it was shown that the SARS-CoV-2 spike protein, binds to the human angiotensin I converting enzyme 2 (ACE2). This molecule is a peptidase expressed at the surface of lung epithelial cells and other tissues, that regulates the renin-angiotensin-aldosterone system. Humans are not equal with respect to the expression levels of the cellular ACE2. Moreover, ACE2 polymorphisms were recently described in human populations. Here we review the most recent evidence that ACE2 expression and/or polymorphism could influence both the susceptibility of people to SARS-CoV-2 infection and the outcome of the COVID-19 disease. Further exploration of the relationship between the virus, the peptidase function of ACE2 and the levels of angiotensin II in SARS-CoV-2 infected patients should help to better understand the pathophysiology of the disease and the multi-organ failures observed in severe COVID-19 cases, particularly heart failure."],"journal":"J Microbiol Immunol Infect","authors":["Devaux, Christian A","Rolain, Jean-Marc","Raoult, Didier"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32414646","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jmii.2020.04.015","keywords":["ace2","covid-19","cardiac failure","hypertension","sars-cov-2"],"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Aldosterone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666991242671554560,"score":9.490897,"similar":[{"pmid":32302706,"pmcid":"PMC7194807","title":"Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.","text":["Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.","The renin-angiotensin system (RAS) is crucial for the physiology and pathology of all the organs. Angiotensin-converting enzyme 2 (ACE2) maintains the homeostasis of RAS as a negative regulator. Recently, ACE2 was identified as the receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus that is causing the pandemic of Coronavirus disease 2019 (COVID-19). Since SARS-CoV-2 must bind with ACE2 before entering the host cells in humans, the distribution and expression of ACE2 may be critical for the target organ of the SARS-CoV-2 infection. Moreover, accumulating evidence has demonstrated the implication of ACE2 in the pathological progression in tissue injury and several chronic diseases, ACE2 may also be essential in the progression and clinical outcomes of COVID-19. Therefore, we summarized the expression and activity of ACE2 in various physiological and pathological conditions, and discussed its potential implication in the susceptibility of SARS-CoV-2 infection and the progression and prognosis of COVID-19 patients in the current review.","Pharmacol Res","Li, Yanwei","Zhou, Wei","Yang, Li","You, Ran","32302706"],"abstract":["The renin-angiotensin system (RAS) is crucial for the physiology and pathology of all the organs. Angiotensin-converting enzyme 2 (ACE2) maintains the homeostasis of RAS as a negative regulator. Recently, ACE2 was identified as the receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus that is causing the pandemic of Coronavirus disease 2019 (COVID-19). Since SARS-CoV-2 must bind with ACE2 before entering the host cells in humans, the distribution and expression of ACE2 may be critical for the target organ of the SARS-CoV-2 infection. Moreover, accumulating evidence has demonstrated the implication of ACE2 in the pathological progression in tissue injury and several chronic diseases, ACE2 may also be essential in the progression and clinical outcomes of COVID-19. Therefore, we summarized the expression and activity of ACE2 in various physiological and pathological conditions, and discussed its potential implication in the susceptibility of SARS-CoV-2 infection and the progression and prognosis of COVID-19 patients in the current review."],"journal":"Pharmacol Res","authors":["Li, Yanwei","Zhou, Wei","Yang, Li","You, Ran"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302706","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.phrs.2020.104833","keywords":["angiotensin-converting enzyme 2","coronavirus disease 2019","diminazene aceturate (pubchem cid: 5284544)","resorcinolnaphthalein (pubchem cid: 337218)","severe acute respiratory syndrome coronavirus 2","xanthenone (pubchem cid: 7020)"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494760648704,"score":336.63},{"pmid":32413319,"title":"SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.","text":["SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.","There is pressing urgency to understand the pathogenesis of the severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2), which causes the disease COVID-19. SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry. The cell subsets targeted by SARS-CoV-2 in host tissues and the factors that regulate ACE2 expression remain unknown. Here, we leverage human, non-human primate, and mouse single-cell RNA-sequencing (scRNA-seq) datasets across health and disease to uncover putative targets of SARS-CoV-2 among tissue-resident cell subsets. We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells. Strikingly, we discovered that ACE2 is a human interferon-stimulated gene (ISG) in vitro using airway epithelial cells and extend our findings to in vivo viral infections. Our data suggest that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection.","Cell","Ziegler, Carly G K","Allon, Samuel J","Nyquist, Sarah K","Mbano, Ian M","Miao, Vincent N","Tzouanas, Constantine N","Cao, Yuming","Yousif, Ashraf S","Bals, Julia","Hauser, Blake M","Feldman, Jared","Muus, Christoph","Wadsworth, Marc H 2nd","Kazer, Samuel W","Hughes, Travis K","Doran, Benjamin","Gatter, G James","Vukovic, Marko","Taliaferro, Faith","Mead, Benjamin E","Guo, Zhiru","Wang, Jennifer P","Gras, Delphine","Plaisant, Magali","Ansari, Meshal","Angelidis, Ilias","Adler, Heiko","Sucre, Jennifer M S","Taylor, Chase J","Lin, Brian","Waghray, Avinash","Mitsialis, Vanessa","Dwyer, Daniel F","Buchheit, Kathleen M","Boyce, Joshua A","Barrett, Nora A","Laidlaw, Tanya M","Carroll, Shaina L","Colonna, Lucrezia","Tkachev, Victor","Peterson, Christopher W","Yu, Alison","Zheng, Hengqi Betty","Gideon, Hannah P","Winchell, Caylin G","Lin, Philana Ling","Bingle, Colin D","Snapper, Scott B","Kropski, Jonathan A","Theis, Fabian J","Schiller, Herbert B","Zaragosi, Laure-Emmanuelle","Barbry, Pascal","Leslie, Alasdair","Kiem, Hans-Peter","Flynn, JoAnne L","Fortune, Sarah M","Berger, Bonnie","Finberg, Robert W","Kean, Leslie S","Garber, Manuel","Schmidt, Aaron G","Lingwood, Daniel","Shalek, Alex K","Ordovas-Montanes, Jose","32413319"],"abstract":["There is pressing urgency to understand the pathogenesis of the severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2), which causes the disease COVID-19. SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry. The cell subsets targeted by SARS-CoV-2 in host tissues and the factors that regulate ACE2 expression remain unknown. Here, we leverage human, non-human primate, and mouse single-cell RNA-sequencing (scRNA-seq) datasets across health and disease to uncover putative targets of SARS-CoV-2 among tissue-resident cell subsets. We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells. Strikingly, we discovered that ACE2 is a human interferon-stimulated gene (ISG) in vitro using airway epithelial cells and extend our findings to in vivo viral infections. Our data suggest that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection."],"journal":"Cell","authors":["Ziegler, Carly G K","Allon, Samuel J","Nyquist, Sarah K","Mbano, Ian M","Miao, Vincent N","Tzouanas, Constantine N","Cao, Yuming","Yousif, Ashraf S","Bals, Julia","Hauser, Blake M","Feldman, Jared","Muus, Christoph","Wadsworth, Marc H 2nd","Kazer, Samuel W","Hughes, Travis K","Doran, Benjamin","Gatter, G James","Vukovic, Marko","Taliaferro, Faith","Mead, Benjamin E","Guo, Zhiru","Wang, Jennifer P","Gras, Delphine","Plaisant, Magali","Ansari, Meshal","Angelidis, Ilias","Adler, Heiko","Sucre, Jennifer M S","Taylor, Chase J","Lin, Brian","Waghray, Avinash","Mitsialis, Vanessa","Dwyer, Daniel F","Buchheit, Kathleen M","Boyce, Joshua A","Barrett, Nora A","Laidlaw, Tanya M","Carroll, Shaina L","Colonna, Lucrezia","Tkachev, Victor","Peterson, Christopher W","Yu, Alison","Zheng, Hengqi Betty","Gideon, Hannah P","Winchell, Caylin G","Lin, Philana Ling","Bingle, Colin D","Snapper, Scott B","Kropski, Jonathan A","Theis, Fabian J","Schiller, Herbert B","Zaragosi, Laure-Emmanuelle","Barbry, Pascal","Leslie, Alasdair","Kiem, Hans-Peter","Flynn, JoAnne L","Fortune, Sarah M","Berger, Bonnie","Finberg, Robert W","Kean, Leslie S","Garber, Manuel","Schmidt, Aaron G","Lingwood, Daniel","Shalek, Alex K","Ordovas-Montanes, Jose"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413319","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.cell.2020.04.035","keywords":["ace2","covid-19","isg","sars-cov-2","human","influenza","interferon","mouse","non-human primate","scrna-seq"],"locations":["Tissues"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319120863233,"score":329.6358},{"pmid":32497323,"title":"Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV (or SARS-CoV-2) Infection.","text":["Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV (or SARS-CoV-2) Infection.","The ongoing outbreak of a new coronavirus (2019-nCoV, or SARS-CoV-2) has caused an epidemic of the acute respiratory syndrome known as COVID-19 in humans. SARS-CoV-2 rapidly spread to multiple regions of China and multiple other countries, posing a serious threat to public health. The spike (S) proteins of SARS-CoV-1 and SARS-CoV-2 may use the same host cellular receptor, angiotensin-converting enzyme 2 (ACE2), for entering into host cells. The affinity between ACE2 and the SARS-CoV-2 S protein is much higher than that of ACE2 binding to the SARS-CoV S protein, explaining why SARS-CoV-2 seems to be more readily transmitted from the human to human. Here, we report that ACE2 can be significantly upregulated after infection of various viruses, including SARS-CoV-1 and SARS-CoV-2, or by the stimulation with inflammatory cytokines such as interferons. We propose that SARS-CoV-2 may positively induce its cellular entry receptor, ACE2, to accelerate its replication and spread; high inflammatory cytokine levels increase ACE2 expression and act as high-risk factors for developing COVID-19, and the infection of other viruses may increase the risk of SARS-CoV-2 infection. Therefore, drugs targeting ACE2 may be developed for the future emerging infectious diseases caused by this cluster of coronaviruses. This article is protected by copyright. All rights reserved.","J Med Virol","Zhuang, Meng-Wei","Cheng, Yun","Zhang, Jing","Jiang, Xue-Mei","Wang, Li","Deng, Jian","Wang, Pei-Hui","32497323"],"abstract":["The ongoing outbreak of a new coronavirus (2019-nCoV, or SARS-CoV-2) has caused an epidemic of the acute respiratory syndrome known as COVID-19 in humans. SARS-CoV-2 rapidly spread to multiple regions of China and multiple other countries, posing a serious threat to public health. The spike (S) proteins of SARS-CoV-1 and SARS-CoV-2 may use the same host cellular receptor, angiotensin-converting enzyme 2 (ACE2), for entering into host cells. The affinity between ACE2 and the SARS-CoV-2 S protein is much higher than that of ACE2 binding to the SARS-CoV S protein, explaining why SARS-CoV-2 seems to be more readily transmitted from the human to human. Here, we report that ACE2 can be significantly upregulated after infection of various viruses, including SARS-CoV-1 and SARS-CoV-2, or by the stimulation with inflammatory cytokines such as interferons. We propose that SARS-CoV-2 may positively induce its cellular entry receptor, ACE2, to accelerate its replication and spread; high inflammatory cytokine levels increase ACE2 expression and act as high-risk factors for developing COVID-19, and the infection of other viruses may increase the risk of SARS-CoV-2 infection. Therefore, drugs targeting ACE2 may be developed for the future emerging infectious diseases caused by this cluster of coronaviruses. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhuang, Meng-Wei","Cheng, Yun","Zhang, Jing","Jiang, Xue-Mei","Wang, Li","Deng, Jian","Wang, Pei-Hui"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32497323","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26139","keywords":["2019-ncov","ace2","covid-19","ifn","isg","sars-cov-2"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668712823848435712,"score":314.30438},{"pmid":32418199,"title":"Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19).","text":["Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19).","Angiotensin-converting enzyme-2 (ACE2) has been established as the functional host receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the current devastating worldwide pandemic of coronavirus disease 2019 (COVID-19). ACE2 is abundantly expressed in a variety of cells residing in many different human organs. In human physiology, ACE2 is a pivotal counter-regulatory enzyme to ACE by the breakdown of angiotensin II, the central player in the renin-angiotensin-aldosterone system (RAAS) and the main substrate of ACE2. Many factors have been associated with both altered ACE2 expression and COVID-19 severity and progression, including age, sex, ethnicity, medication and several co-morbidities, such as cardiovascular disease and metabolic syndrome. Although ACE2 is widely distributed in various human tissues and many of its determinants have been well recognised, ACE2-expressing organs do not equally participate in COVID-19 pathophysiology, implying that other mechanisms are involved in orchestrating cellular infection resulting in tissue damage. Reports of pathologic findings in tissue specimens of COVID-19 patients are rapidly emerging and confirm the established role of ACE2 expression and activity in disease pathogenesis. Identifying pathologic changes caused by SARS-CoV-2 infection is crucially important as it has major implications for understanding COVID-19 pathophysiology and the development of evidence-based treatment strategies. Currently, many interventional strategies are being explored in ongoing clinical trials, encompassing many drug classes and strategies, including antiviral drugs, biological response modifiers and RAAS inhibitors. Ultimately, prevention is key to combat COVID-19 and appropriate measures are being taken accordingly, including development of effective vaccines. In this review, we describe the role of ACE2 in COVID-19 pathophysiology, including factors influencing ACE2 expression and activity in relation to COVID-19 severity. In addition, we discuss the relevant pathological changes resulting from SARS-CoV-2 infection. Finally, we highlight a selection of potential treatment modalities for COVID-19. This article is protected by copyright. All rights reserved.","J Pathol","Bourgonje, Arno R","Abdulle, Amaal Eman","Timens, Wim","Hillebrands, Jan-Luuk","Navis, Gerjan J","Gordijn, Sanne J","Bolling, Marieke C","Dijkstra, Gerard","Voors, Adriaan A","Osterhaus, Albert D M E","van der Voort, Peter H J","Mulder, Douwe J","van Goor, Harry","32418199"],"abstract":["Angiotensin-converting enzyme-2 (ACE2) has been established as the functional host receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the current devastating worldwide pandemic of coronavirus disease 2019 (COVID-19). ACE2 is abundantly expressed in a variety of cells residing in many different human organs. In human physiology, ACE2 is a pivotal counter-regulatory enzyme to ACE by the breakdown of angiotensin II, the central player in the renin-angiotensin-aldosterone system (RAAS) and the main substrate of ACE2. Many factors have been associated with both altered ACE2 expression and COVID-19 severity and progression, including age, sex, ethnicity, medication and several co-morbidities, such as cardiovascular disease and metabolic syndrome. Although ACE2 is widely distributed in various human tissues and many of its determinants have been well recognised, ACE2-expressing organs do not equally participate in COVID-19 pathophysiology, implying that other mechanisms are involved in orchestrating cellular infection resulting in tissue damage. Reports of pathologic findings in tissue specimens of COVID-19 patients are rapidly emerging and confirm the established role of ACE2 expression and activity in disease pathogenesis. Identifying pathologic changes caused by SARS-CoV-2 infection is crucially important as it has major implications for understanding COVID-19 pathophysiology and the development of evidence-based treatment strategies. Currently, many interventional strategies are being explored in ongoing clinical trials, encompassing many drug classes and strategies, including antiviral drugs, biological response modifiers and RAAS inhibitors. Ultimately, prevention is key to combat COVID-19 and appropriate measures are being taken accordingly, including development of effective vaccines. In this review, we describe the role of ACE2 in COVID-19 pathophysiology, including factors influencing ACE2 expression and activity in relation to COVID-19 severity. In addition, we discuss the relevant pathological changes resulting from SARS-CoV-2 infection. Finally, we highlight a selection of potential treatment modalities for COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Pathol","authors":["Bourgonje, Arno R","Abdulle, Amaal Eman","Timens, Wim","Hillebrands, Jan-Luuk","Navis, Gerjan J","Gordijn, Sanne J","Bolling, Marieke C","Dijkstra, Gerard","Voors, Adriaan A","Osterhaus, Albert D M E","van der Voort, Peter H J","Mulder, Douwe J","van Goor, Harry"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32418199","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/path.5471","keywords":["angiotensin-converting enzyme-2 (ace2)","coronavirus disease 2019 (covid-19)","organ involvement","pathology","pathophysiology","renin-angiotensin-aldosterone system (raas)","risk factors","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)","treatment"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667058206808997889,"score":307.7669},{"pmid":32264791,"pmcid":"PMC7188049","title":"Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.","text":["Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.","ACE2 (angiotensin-converting enzyme 2) has a multiplicity of physiological roles that revolve around its trivalent function: a negative regulator of the renin-angiotensin system, facilitator of amino acid transport, and the severe acute respiratory syndrome-coronavirus (SARS-CoV) and SARS-CoV-2 receptor. ACE2 is widely expressed, including, in the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue. ACE2 has recently been identified as the SARS-CoV-2 receptor, the infective agent responsible for coronavirus disease 2019, providing a critical link between immunity, inflammation, ACE2, and cardiovascular disease. Although sharing a close evolutionary relationship with SARS-CoV, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues, allowing for stronger binding affinity with the human ACE2 receptor, which may account for the greater pathogenicity of SARS-CoV-2. The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing. The ACE2 system is a critical protective pathway against heart failure with reduced and preserved ejection fraction including, myocardial infarction and hypertension, and against lung disease and diabetes mellitus. The control of gut dysbiosis and vascular permeability by ACE2 has emerged as an essential mechanism of pulmonary hypertension and diabetic cardiovascular complications. Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions associated with an activated renin-angiotensin system. rhACE2 (recombinant human ACE2) has completed clinical trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, respectively. Our review summarizes the progress over the past 20 years, highlighting the critical role of ACE2 as the novel SARS-CoV-2 receptor and as the negative regulator of the renin-angiotensin system, together with implications for the coronavirus disease 2019 pandemic and associated cardiovascular diseases.","Circ Res","Gheblawi, Mahmoud","Wang, Kaiming","Viveiros, Anissa","Nguyen, Quynh","Zhong, Jiu-Chang","Turner, Anthony J","Raizada, Mohan K","Grant, Maria B","Oudit, Gavin Y","32264791"],"abstract":["ACE2 (angiotensin-converting enzyme 2) has a multiplicity of physiological roles that revolve around its trivalent function: a negative regulator of the renin-angiotensin system, facilitator of amino acid transport, and the severe acute respiratory syndrome-coronavirus (SARS-CoV) and SARS-CoV-2 receptor. ACE2 is widely expressed, including, in the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue. ACE2 has recently been identified as the SARS-CoV-2 receptor, the infective agent responsible for coronavirus disease 2019, providing a critical link between immunity, inflammation, ACE2, and cardiovascular disease. Although sharing a close evolutionary relationship with SARS-CoV, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues, allowing for stronger binding affinity with the human ACE2 receptor, which may account for the greater pathogenicity of SARS-CoV-2. The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing. The ACE2 system is a critical protective pathway against heart failure with reduced and preserved ejection fraction including, myocardial infarction and hypertension, and against lung disease and diabetes mellitus. The control of gut dysbiosis and vascular permeability by ACE2 has emerged as an essential mechanism of pulmonary hypertension and diabetic cardiovascular complications. Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions associated with an activated renin-angiotensin system. rhACE2 (recombinant human ACE2) has completed clinical trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, respectively. Our review summarizes the progress over the past 20 years, highlighting the critical role of ACE2 as the novel SARS-CoV-2 receptor and as the negative regulator of the renin-angiotensin system, together with implications for the coronavirus disease 2019 pandemic and associated cardiovascular diseases."],"journal":"Circ Res","authors":["Gheblawi, Mahmoud","Wang, Kaiming","Viveiros, Anissa","Nguyen, Quynh","Zhong, Jiu-Chang","Turner, Anthony J","Raizada, Mohan K","Grant, Maria B","Oudit, Gavin Y"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32264791","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1161/CIRCRESAHA.120.317015","keywords":["cardiovascular diseases","coronavirus","dysbiosis","heart failure","renin-angiotensin system"],"locations":["kidneys"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491949416450,"score":305.18137}]}